Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
AuthorsWoll, Penella J
Le Chevalier, T
Perez Manga, G
AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractRaltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles were given (median two, range one to four). The drug was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in only one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive as second line therapy for small-cell lung cancer.
CitationPhase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. 1997, 76 (2):264-5 Br. J. Cancer
JournalBritish Journal of Cancer
- Mature results from three large controlled studies with raltitrexed ('Tomudex').
- Authors: Cunningham D
- Issue date: 1998
- Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
- Authors: Sato A, Kurihara M, Horikoshi N, Aiba K, Kikkawa N, Shirouzu K, Mitachi Y, Sakata Y, Wakui A
- Issue date: 1999 Sep
- A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
- Authors: Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J, Seymour L
- Issue date: 1996 Aug
- A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
- Authors: Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ
- Issue date: 1999 Sep
- Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.
- Authors: Blay JY, Judson I, Rodenhuis S, Hermans C, Smith M, van Glabbeke M, Verweij J
- Issue date: 1999 Nov